title: Potential benefits of berberine in the management of perimenopausal syndrome.
abstract: Cardiovascular diseases are one of the leading causes of morbidity and mortality in women after menopause and 56% of all causes of death in Western European countries. Nowadays, with increasing life span, women spend approximately one-third of their life-time in postmenopausal state; therefore, the development of new strategies to improve the prevention and treatment of menopause-associated pathologies is important topic in clinical practice. The studies to assess the safety of hormone replacement therapy in women with estrogen deficiency have not been conclusive due to the relative contraindications; therefore, hormone replacement therapy is prescribed only in selected cases and for a limited time. For this reason, today women are encouraged to use naturally available compounds to prevent or to attenuate menopausal symptoms and correlated pathologies, with fewer side effects. Among these compounds, berberine, an isoquinoline alkaloid derived from plants of the generis Berberis, has been recognized as being capable of decreasing oxidative stress, LDL, triglycerides, and insulin resistance and of improving the mood. This review describes the cellular and clinical effects associated with the use of berberine, which suggest that this molecule could be an effective natural supplement to ensure a smooth peri- and postmenopausal transition.
authors.affiliation: Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
authors.forename: Cristiana
authors.identifier: 0000-0002-6740-5331
authors.initials: C
authors.lastname: Caliceti
authors.affiliation: Department of Medical Sciences, University of Ferrara, Ferrara, Italy ; Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Rizzo
authors.affiliation: Department of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy.
authors.forename: Arrigo Francesco Giuseppe
authors.initials: AF
authors.lastname: Cicero
mesh_terms: D001599:Berberine / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008077:Lipoproteins, LDL / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects*; D047648:Perimenopause; D014280:Triglycerides / Q000097:blood
chemical_list: D008077:Lipoproteins, LDL; D014280:Triglycerides; D001599:Berberine